FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2977685627> ?p ?o ?g. }

• W2977685627 endingPage "e459" @default.
• W2977685627 startingPage "e451" @default.
• W2977685627 abstract "Abstract Background Bevacizumab, a VEGF-A inhibitor, in combination with chemotherapy, has proven to increase progression-free survival (PFS) and overall survival in multiple lines of therapy of metastatic colorectal cancer (mCRC). The angiogenic factor angiopoetin-2 (Ang-2) is associated with poor prognosis in many cancers, including mCRC. Preclinical models demonstrate improved activity when inhibiting both VEGF-A and Ang-2, suggesting that the dual VEGF-A and Ang-2 blocker vanucizumab (RO5520985 or RG-7221) may improve clinical outcomes. This phase II trial evaluated the efficacy of vanucizumab plus modified (m)FOLFOX-6 (folinic acid (leucovorin), fluorouracil (5-FU) and oxaliplatin) versus bevacizumab/mFOLFOX-6 for first-line mCRC. Patients and Methods All patients received mFOLFOX-6 and were randomized 1:1 to also receive vanucizumab 2,000 mg or bevacizumab 5 mg/kg every other week. Oxaliplatin was given for eight cycles; other agents were continued until disease progression or unacceptable toxicity for a maximum of 24 months. The primary endpoint was investigator-assessed PFS. Results One hundred eighty-nine patients were randomized (vanucizumab, n = 94; bevacizumab, n = 95). The number of PFS events was comparable (vanucizumab, n = 39; bevacizumab, n = 43). The hazard ratio was 1.00 (95% confidence interval, 0.64–1.58; p = .98) in a stratified analysis based on number of metastatic sites and region. Objective response rate was 52.1% and 57.9% in the vanucizumab and bevacizumab arm, respectively. Baseline plasma Ang-2 levels were prognostic in both arms but not predictive for treatment effects on PFS of vanucizumab. The incidence of adverse events of grade ≥3 was similar between treatment arms (83.9% vs. 82.1%); gastrointestinal perforations (10.8% vs. 8.4%) exceeded previously reported rates in this setting. Hypertension and peripheral edema were more frequent in the vanucizumab arm. Conclusion Vanucizumab/mFOLFOX-6 did not improve PFS and was associated with increased rates of antiangiogenic toxicity compared with bevacizumab/mFOLFOX-6. Our results suggest that Ang-2 is not a relevant therapeutic target in first-line mCRC." @default.
• W2977685627 created "2019-10-10" @default.
• W2977685627 creator A5001410842 @default.
• W2977685627 creator A5021255868 @default.
• W2977685627 creator A5028472820 @default.
• W2977685627 creator A5028818673 @default.
• W2977685627 creator A5030078141 @default.
• W2977685627 creator A5034109602 @default.
• W2977685627 creator A5038374068 @default.
• W2977685627 creator A5045435374 @default.
• W2977685627 creator A5046311492 @default.
• W2977685627 creator A5052605913 @default.
• W2977685627 creator A5053620668 @default.
• W2977685627 creator A5053795893 @default.
• W2977685627 creator A5058102434 @default.
• W2977685627 creator A5058692581 @default.
• W2977685627 creator A5059078840 @default.
• W2977685627 creator A5062003452 @default.
• W2977685627 creator A5068913222 @default.
• W2977685627 creator A5071430061 @default.
• W2977685627 creator A5072809476 @default.
• W2977685627 creator A5076521943 @default.
• W2977685627 creator A5077985050 @default.
• W2977685627 creator A5078694638 @default.
• W2977685627 creator A5081173716 @default.
• W2977685627 creator A5090464803 @default.
• W2977685627 creator A5091000505 @default.
• W2977685627 creator A5091727687 @default.
• W2977685627 date "2019-09-30" @default.
• W2977685627 modified "2023-10-06" @default.
• W2977685627 title "The McCAVE Trial: Vanucizumab plus mFOLFOX-6 Versus Bevacizumab plus mFOLFOX-6 in Patients with Previously Untreated Metastatic Colorectal Carcinoma (mCRC)" @default.
• W2977685627 cites W1968014316 @default.
• W2977685627 cites W1976558864 @default.
• W2977685627 cites W1977379029 @default.
• W2977685627 cites W1985335252 @default.
• W2977685627 cites W1987497125 @default.
• W2977685627 cites W1999099046 @default.
• W2977685627 cites W2002422795 @default.
• W2977685627 cites W2012852444 @default.
• W2977685627 cites W2019607817 @default.
• W2977685627 cites W2022066554 @default.
• W2977685627 cites W2048946249 @default.
• W2977685627 cites W2052042813 @default.
• W2977685627 cites W2084606377 @default.
• W2977685627 cites W2087486104 @default.
• W2977685627 cites W2099028752 @default.
• W2977685627 cites W2107252679 @default.
• W2977685627 cites W2113832885 @default.
• W2977685627 cites W2118266456 @default.
• W2977685627 cites W2122927195 @default.
• W2977685627 cites W2123325613 @default.
• W2977685627 cites W2130867283 @default.
• W2977685627 cites W2133758413 @default.
• W2977685627 cites W2139542186 @default.
• W2977685627 cites W2144727447 @default.
• W2977685627 cites W2145441158 @default.
• W2977685627 cites W2147183055 @default.
• W2977685627 cites W2154369198 @default.
• W2977685627 cites W2161593277 @default.
• W2977685627 cites W2192931230 @default.
• W2977685627 cites W2295851099 @default.
• W2977685627 cites W2588681261 @default.
• W2977685627 cites W2592503476 @default.
• W2977685627 cites W2775716946 @default.
• W2977685627 cites W2883437756 @default.
• W2977685627 cites W308164218 @default.
• W2977685627 doi "https://doi.org/10.1634/theoncologist.2019-0291" @default.
• W2977685627 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7066709" @default.
• W2977685627 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32162804" @default.
• W2977685627 hasPublicationYear "2019" @default.
• W2977685627 type Work @default.
• W2977685627 sameAs 2977685627 @default.
• W2977685627 citedByCount "24" @default.
• W2977685627 countsByYear W29776856272020 @default.
• W2977685627 countsByYear W29776856272021 @default.
• W2977685627 countsByYear W29776856272022 @default.
• W2977685627 countsByYear W29776856272023 @default.
• W2977685627 crossrefType "journal-article" @default.
• W2977685627 hasAuthorship W2977685627A5001410842 @default.
• W2977685627 hasAuthorship W2977685627A5021255868 @default.
• W2977685627 hasAuthorship W2977685627A5028472820 @default.
• W2977685627 hasAuthorship W2977685627A5028818673 @default.
• W2977685627 hasAuthorship W2977685627A5030078141 @default.
• W2977685627 hasAuthorship W2977685627A5034109602 @default.
• W2977685627 hasAuthorship W2977685627A5038374068 @default.
• W2977685627 hasAuthorship W2977685627A5045435374 @default.
• W2977685627 hasAuthorship W2977685627A5046311492 @default.
• W2977685627 hasAuthorship W2977685627A5052605913 @default.
• W2977685627 hasAuthorship W2977685627A5053620668 @default.
• W2977685627 hasAuthorship W2977685627A5053795893 @default.
• W2977685627 hasAuthorship W2977685627A5058102434 @default.
• W2977685627 hasAuthorship W2977685627A5058692581 @default.
• W2977685627 hasAuthorship W2977685627A5059078840 @default.
• W2977685627 hasAuthorship W2977685627A5062003452 @default.
• W2977685627 hasAuthorship W2977685627A5068913222 @default.
• W2977685627 hasAuthorship W2977685627A5071430061 @default.
• W2977685627 hasAuthorship W2977685627A5072809476 @default.
• W2977685627 hasAuthorship W2977685627A5076521943 @default.

• next